Department of Pharmacotherapy
Title: Professor, Department of Pharmacotherapy Executive Director, Outcomes Research Center Director of Outcomes, Program in Personalized Health Care
L. S. Skaggs Research Institute Room 4781
Phone: (801) 581-3182
Fax: (801) 587-7923
Diana I. Brixner, RPh, PhD, FAMCP, is currently Professor in the Department of Pharmacotherapy at the University of Utah College Of Pharmacy in Salt Lake City. She is also Executive Director of the Pharmacotherapy Outcomes Research Center, affiliated with the University of Utah Health Sciences Center, where she focuses on the design, conduct, training, and communication of pharmacoeconomic and outcomes research studies to demonstrate the value of pharmaceutical therapy. She is the Director of Outcomes for the Program in Personalized Health Care affiliated with the University of Utah Health Sciences Center, focusing on the tailoring of health care to the individual characteristics of the patient. These characteristics can include environment, social history, health history, family history, genetics, proteomics, and more.
During her career, Dr. Brixner has published numerous articles in peer-reviewed journals, including the Journal of National Cancer Center Networks, Value in Health, Pharmacoepidemiology and Drug Safety, the American Journal of Managed Care and the Journal of Managed Care Pharmacy, authored three book chapters, has one issued patent, has been an invited speaker at a variety of professional meetings, and has presented numerous continuing education programs. She served a two-year term on the Executive Board of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and is the immediate past president of this association. She has served on the Health Outcomes Committee of the Pharmaceutical Research Manufacturers Association. Diana has received the honor of being named a Fellow of the Academy of Managed Care Pharmacy (AMCP), which recognizes sustained excellence in the pharmacy profession, and exceptional contributions, long-term commitment and active participation in the Academy.
PhD University of Utah
BS University of Rhode Island
- Health care decision makers' use of comparative effectiveness research: report from a series of focus groups. Villa L, Warholak TL, Hines LE, Taylor AM, Brown M, et al. Journal of Managed Care Pharmacy. 2013; 19(9):745-54.
- Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer. Stenehjem DD, Yoo M, Unni SK, Singhal M, Bauer H, et al. Breast Cancer (Dove Medical Press). 2014; 6:169-77.
- Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. McAdam-Marx C, Bellows BK, Unni S, Wygant G, Mukherjee J, et al. Journal of Managed Care & Specialty Pharmacy. 2014; 20(7):691-700.
- Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, et al. Leukemia & Lymphoma. 2015; :1-11.
- Need for multicriteria evaluation of generic drug policies. Kaló Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Ágh T, et al. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015; 18(2):346-51.